Background:
The characteristics of drug resistant hypertension against angiotensin II receptor blocker (ARB) and angiotensin-converting enzyme inhibitor (ACEI) are still unclear. We aimed to evaluate the clinical characteristics of these patients.
Methods: Seventy three uncomplicated essential hypertensives [mean age 69.3 years, 31 diabetes mellitus (DM)] were recruited. We performed a prospective cross-over study using ambulatory BP monitoring of the baseline and 12-weeks of each candesartan and lisinopril treatments. A small dose of thiazide-diuretic was added if necessary. We further classified patients for 2 groups: non-responder (24hr SBP reduction Ͻ15mmHg with both candesartanϩdiuretic and lisinoprilϩdiuretic , nϭ19), responder (24hr SBP reduction Ͼ15mmHg with either drug with or without diuretic, nϭ42)
Results: Diabetes was more common in non-responder group than in responder group (73.7% vs. 40.5%, Pϭ0.026). The non-responder rate was significantly higher in DM group than in non-DM group: candesartan (DM 45.2% vs. non-DM 16.7%, Pϭ0.026). The antihypertensive effect of each drug on 24hr SBP was stronger in responder group than in non-responder group: (candesartan: -16mmHg vs. -1mmHg, Pϭ0.004; lisinopril: -15mmHg vs. 0mmHg, Pϭ0.003) but the age, gender, BMI, LV mass index were similar between the groups.
Conclusion:
In diabetic hypertensive patients, the antihypertensive effect of ARB and ACE inhibitor was less potent than in non-diabetic patients. Multiple drug therapy is needed for treatments of these patients.
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Several randomized long-term clinical trials have shown that either an angiotensin-converting enzyme (ACE)-inhibitor or an angiotensin II receptor blocker (ARB) prevents new-onset diabetes, but no study has directly compared the two classes of drugs. We therefore performed a meta-analysis of each long-term randomized clinical trial (RCT), comparing each drug class with all other comparators, and also comparing each drug with a common comparator (using the method of Bucher et al., J Clin Epidemiol., 1997; 50:683-691 
